Director/PDMR Shareholding
August 18 2008 - 9:57AM
UK Regulatory
RNS Number : 5500B
Research Pharmaceutical SRV, Inc
18 August 2008
ReSearch Pharmaceutical Services, Inc.
Grant of Options
ReSearch Pharmaceutical Services, Inc.("RPS" or the "Company"), a leading provider of integrated clinical development outsourcing
solutions to the bio-pharmaceutical industry, is pleased to announce that is granted stock options (the "Grant") over a total of 10,000
shares of common stock to certain directors of the Company on August 15, 2008.
The stock options are exercisable at $3.70 per share being the most recent executed trade as of the date of the grant August 15, 2008.
The options will vest over the next three calendar years, with one third of the options being made available to the option holder each
successive year. The fully vested options are exercisable at any time between August 15, 2011 and August 15, 2021 being a period of between
three and ten years from the date of grant.
The Grant has been made to the following RPS directors:
Jack Dean, Non-executive Director 5,000
Warren Myers, Non-executive Director 5,000
Following the Grant each of Jack Dean and Warren Myers hold options totaling 5,000 shares each and are not holding any other share
amounts of RPS common stock.
For further information please contact:
ReSearch Pharmaceutical Services, Inc.: +1-215-540-0700
Daniel M. Perlman, Chairman & Chief
Executive Officer
Steven Bell, Chief Financial Officer
Nominated Adviser and UK Broker: +44-20-7012-2100
Arbuthnot Securities Limited
James Steel/Richard Tulloch
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSUWVORWNRWAAR
Res.Phm.Reg S (LSE:RPSE)
Historical Stock Chart
From May 2024 to Jun 2024
Res.Phm.Reg S (LSE:RPSE)
Historical Stock Chart
From Jun 2023 to Jun 2024